Highest out-of-pocket cancer spending for Medicare patients without supplement

November 23, 2016

Which Medicare beneficiaries shoulder the highest out-of-pocket costs after a cancer diagnosis? The answer is those beneficiaries without supplemental insurance, according to a new article published online by JAMA Oncology.

Ensuring the financial security of elderly patients with cancer requires an understanding of which patients experience high out-of-pocket costs and which services contribute to these costs.

Amol K. Narang, M.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues analyzed survey data for 18,166 Medicare beneficiaries who participated in waves of the Health and Retirement Study, a nationally representative survey of U.S. adults older than 50, from 2002 through 2012. During the study period, 1,409 participants (7.8 percent) were diagnosed with cancer; their median age was 73 and almost 54 percent were male.

Average annual out-of-pocket expenses for all Health and Retirement Study participants were $3,737. A new diagnosis of cancer or a common chronic noncancer condition was associated with increased odds of incurring higher costs, according to the report.

The type, or lack, of supplementary insurance was associated with average annual out-of-pocket costs incurred after a cancer diagnosis, the authors report. Those survey participants with private supplemental insurance, without supplemental insurance or with Medicare benefits through an HMO all had increased odds of higher out-of-pocket costs compared with beneficiaries with Medicaid or Veterans Health Administration coverage.

The average annual out-of-pocket costs following cancer diagnosis for Medicare beneficiaries were $2,116 with Medicaid coverage; $2,367 with Veterans Health Administration coverage; $5,492 with employer-sponsored insurance; $5,670 with Medigap; $5,976 with a Medicare HMO; and $8,115 with traditional fee-for-service Medicare with no supplementary coverage, the authors report.

Hospitalizations were the primary reason for higher out-of-pocket costs, the report notes.

Medicare beneficiaries with a new cancer diagnosis and Medicare alone had average out-of-pocket costs that were almost 24 percent of their household income. In addition, about 10 percent of beneficiaries had out-of-pocket costs that topped 63 percent of their total household income, according to the article.

Limitations of the study include that out-of-pocket expenditures were self-reported by patients.

"Proposals for Medicare reform that restructure the design of benefits for hospital services and incorporate an OOP [out-of-pocket] maximum may help alleviate the risk of financial burden for future beneficiaries, as can interventions that reduce hospitalizations in this population," the study concludes.
(JAMA Oncol. Published online November 23, 2016. doi:10.1001/jamaoncol.2016.4865; available pre-embargo at the For The Media website.)

Editor's Note: The article contains funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.